22Oct 2023
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

The phase 2 trial investigated the efficacy and safety of tarlatamab, administered intravenously every 2 weeks at doses of 10 mg and 100 mg, in previously treated small-cell lung cancer patients. Objective responses were seen in 40% of the 10-mg group and 32% of the 100-mg group, with 59% of the responders displaying a response duration of at least 6 months. Additionally, the median progression-free survival was 4.9 months and 3.9 months in the 10-mg and 100-mg groups, respectively. Overall survival at 9 months was estimated at 68% and 66% for the 10-mg and 100-mg groups, respectively. Common adverse events included cytokine-release syndrome, decreased appetite, and pyrexia. The study demonstrated promising antitumor activity and manageable safety profiles for tarlatamab in small-cell lung cancer patients.

  • #oncology

Like

Save

Share